Venetoclax (ABT-199) is a highly selective BCL-2 inhibitor 10, which was approved for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and in combination therapy with azacytidine or decitabine or low-dose cytarabine to treat adult acute myeloid leukemia (AML) patients, representing a paradigm change of AML treatment 11, 12. Here, BCL2 is linked to acute myeloid leukemia.